share_log

Short Interest in Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) Expands By 30.3%

Short Interest in Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) Expands By 30.3%

对创新制药公司(OTCMKTS: IPIX)的空头兴趣扩大了30.3%
kopsource ·  2023/04/19 16:44

Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX – Get Rating) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 620,700 shares, an increase of 30.3% from the March 15th total of 476,200 shares. Based on an average daily volume of 738,300 shares, the short-interest ratio is presently 0.8 days.

创新制药公司(OTCMKTS: IPIX — 获取评级)是3月份空头利息大幅增加的目标。截至3月31日,空头利息总额为62.07万股,较3月15日的476,200股增加了30.3%。根据738,300股的平均每日交易量,目前的空头利率为0.8天。

Innovation Pharmaceuticals Stock Down 10.0 %

创新制药股下跌10.0%

Shares of OTCMKTS:IPIX traded down $0.00 during midday trading on Wednesday, hitting $0.02. The stock had a trading volume of 203,046 shares, compared to its average volume of 546,743. The stock has a 50 day moving average price of $0.02 and a two-hundred day moving average price of $0.02. Innovation Pharmaceuticals has a 1 year low of $0.01 and a 1 year high of $0.06.

周三午盘交易中,OTCMKTS: IPIX的股价下跌了0.00美元,触及0.02美元。该股的交易量为203,046股,而平均成交量为546,743股。该股的50天移动平均价格为0.02美元,200天移动平均线价格为0.02美元。创新制药的1年低点为0.01美元,为1年高点0.06美元。

Get
获取
Innovation Pharmaceuticals
创新制药
alerts:
警报:

About Innovation Pharmaceuticals

关于创新制药

(Get Rating)

(获取评分)

Innovation Pharmaceuticals, Inc is a clinical stage biotechnology company. It engages in developing therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. The firm's lead cancer compound, Kevetrin, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers.

创新制药公司是一家临床阶段的生物技术公司。它致力于开发具有抗感染、肿瘤、抗炎和皮肤病学应用的疗法。该公司的主要癌症化合物Kevetrin是一种抗癌药物,已在临床前研究中证明了调节p53途径和攻击癌症的能力。

Read More

阅读更多

  • Get a free copy of the StockNews.com research report on Innovation Pharmaceuticals (IPIX)
  • ASML Reports Massive Growth, Management Points To Sluggish 2023
  • Will Analyst Boost Send Lockheed Martin Shares Up, Up and Away?
  • Mullen Automotive: Is The Bloom Off The Rose?
  • Diversified Abbott Laboratories Could Reverse And Move Higher
  • Okta Reversal In Progress While Catalysts Approach
  • 免费获取 StockNews.com 关于创新制药 (IPIX) 的研究报告的副本
  • ASML报告了大规模增长,管理层指出2023年表现疲软
  • 分析师 Boost 会让洛克希德·马丁公司的股价上涨、上涨和下跌吗?
  • Mullen Automotive:是玫瑰花的吗?
  • 多元化的雅培实验室可能会逆转并走高
  • 催化剂接近时Okta的逆转正在进行中

Receive News & Ratings for Innovation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

接收创新制药日报的新闻和收视率 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Innovation Pharmicals及相关公司最新新闻和分析师评级的简明每日摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发